Hung Do, Ph.D., Chief Science Officer
Hung Do, Ph.D.

Hung Do, Ph.D.

Chief Science Officer

LinkedIn

Hung Do joined Amicus in December 2013 and currently serves as Chief Science Officer. Dr. Hung Do brings experience in the field of lysosomal diseases (LDs) and enzyme replacement therapies (ERTs). Prior to joining Amicus, he was a Co-founder and Chief Scientific Officer of Callidus Biopharma, a privately-held biologics company that was acquired by Amicus. Prior to founding Callidus, he headed early discovery research to decipher the mechanism of action for small molecule pharmacological chaperones at Amicus. He previously helped to demonstrate proof-of-concept for ERTs, and served as the project leader for a second-generation Pompe ERT at Genzyme. Dr. Do also led molecular biology, cell culture and purification work and helped develop an in vitro protein modification process for improving drug targeting for protein therapeutics at Novazyme, which was acquired by Genzyme.

Dr. Do holds a Ph.D. in medical Biochemistry and genetics from Texas A&M University (mentored by Professor Arthur E. Johnson) and was a post-doctoral fellow in Hematology/Oncology at Emory University (Dr. John S. Lollar). Dr. Do utilizes his focused training in protein synthesis, folding & trafficking to develop better targeted therapeutic treatments for genetic diseases.

Back to Senior Management Team